Jacob R. Bledsoe

Jacob R. Bledsoe

Auto-generated profile, based on publicly available information

Jacob R. Bledsoe

Department of Pathology, Boston Children’s Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2018 in APMIS
Verified
Journal Article
Closed access
PDF file
JBJacob R. Bledsoe
Jacob R. Bledsoe
EDEmanuel Della‐Torre
Emanuel Della‐Torre
LRLucrezia Rovati
Lucrezia Rovati
VDVikram Deshpande
Vikram Deshpande

28 December 2017 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
JBJacob R. Bledsoe
Jacob R. Bledsoe
ZWZachary S. Wallace
Zachary S. Wallace
JSJohn H. Stone
John H. Stone
VDVikram Deshpande
Vikram Deshpande
JFJudith A. Ferry
Judith A. Ferry

22 January 2021 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
XZXiaoqin Zhu
Xiaoqin Zhu
SJSarah Jamshed
Sarah Jamshed
JZJian Zou
Jian Zou
AAAzniv Azar
Azniv Azar
XMXiuling Meng
Xiuling Meng
JBJacob R. Bledsoe
Jacob R. Bledsoe

5 September 2020 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
EWErik A. Williams
Erik A. Williams
MMMeagan Montesion
Meagan Montesion
BABrian M. Alexander
Brian M. Alexander
SRShakti H. Ramkissoon
Shakti H. Ramkissoon
JEJulia A. Elvin
Julia A. Elvin
MMMark C. Mochel
Mark C. Mochel
Mutations in the tumor suppressor CYLD, known to be causative of cylindromas, were recently described in a subset of high-risk (hr) HPV-positive head and neck squamous cell carcinomas (HNSCC). Pathologic and genetic characterization of these CYLD-mutant carcinomas, however, remains limited. Here, we investigated whether CYLD mutations characterize a histopathologically and genomically distinct subset of hrHPV-positive HNSCC. Comprehensive genomic profiling via hybrid capture-based DNA sequencing was performed on 703 consecutive head and neck carcinomas with hrHPV sequences, identifying 148 unique cases (21%) harboring CYLD mutations. Clinical data, pathology reports, and histopathology were reviewed. CYLD mutations included homozygous deletions (n = 61/148; 41%), truncations (n = 52; 35%), missense (n = 26; 18%) and splice-site (n = 9; 6%) mutations, and in-frame deletion (n = 1; 1%). Among hrHPV-positive HNSCC, the CYLD-mutant cohort showed substantially lower tumor mutational burden than CYLD-wildtype cases (n = 555) (median 2.6 vs. 4.4 mut/Mb, p < 0.00001) and less frequent alterations in PIK3CA (11% vs. 34%, p < 0.0001), KMT2D (1% vs. 16%, p < 0.0001), and FBXW7 (3% vs. 11%, p = 0.0018). Male predominance (94% vs. 87%), median age (58 vs. 60 years), and detection of HPV16 (95% vs. 89%) were similar. On available histopathology, 70% of CYLD-mutant HNSCC (98/141 cases) contained hyalinized material, consistent with basement membrane inclusions, within crowded aggregates of tumor cells. Only 7% of CYLD-wildtype cases demonstrated this distinctive pattern (p < 0.0001). Histopathologic patterns of CYLD-mutant HNSCC lacking basement membrane inclusions included nonkeratinizing (n = 22, 16%), predominantly nonkeratinizing (nonkeratinizing SCC with focal maturation; n = 10, 7%), and keratinizing (n = 11, 8%) patterns. The latter two groups showed significantly higher frequency of PTEN alterations compared with other CYLD-mutant cases (38% [8/21] vs. 7% [8/120], p = 0.0004). Within our cohort of hrHPV-positive HNSCCs, CYLD mutations were frequent (21%) and demonstrated distinctive clinical, histopathologic, and genomic features that may inform future study of prognosis and treatment.

1 September 2020 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
JBJacob R. Bledsoe
Jacob R. Bledsoe
JFJudith A. Ferry
Judith A. Ferry
ANAzfar Neyaz
Azfar Neyaz
LBLeonardo Boiocchi
Leonardo Boiocchi
CSCara Strock
Cara Strock
VDVikram Deshpande
Vikram Deshpande
Lymphadenopathy is common in patients with immunoglobulin G4-related disease (IgG4-RD). However, the described histopathologic features of IgG4-related lymphadenopathy have been shown to be largely nonspecific. In an attempt to identify features specific for nodal IgG4-RD we examined the histopathologic features of lymph nodes from 41 patients with established IgG4-RD, with comparison to 60 lymph nodes from patients without known or subsequent development of IgG4-RD. An increase in immunoglobulin (Ig) G4-positive plasma cells >100/HPF and IgG4/IgG ratio >40% was identified in 51% of IgG4-RD cases and 20% of control cases. Localization of increased IgG4-positive plasma cells and IgG4/IgG ratio to extrafollicular zones was highly associated with IgG4-RD, particularly when identified in regions of nodal fibrosis (P<0.0001; specificity: 98.3%), or in the context of marked interfollicular expansion (P=0.022; specificity: 100%). Other features characteristic of IgG4-RD included frequent eosinophils associated with IgG4-positive plasma cells, phlebitis (P=0.06), and perifollicular granulomas (P=0.16). The presence of an isolated increase in intrafollicular IgG4-positive plasma cells and IgG4/IgG ratio was more frequently present in control cases than IgG4-RD (P<0.0001). This study confirms that increased IgG4-positive plasma cells and IgG4/IgG ratio are neither sensitive nor specific for the diagnosis of IgG4-related lymphadenopathy, and most described morphologic patterns are nonspecific. In contrast, nodal involvement by IgG4-rich fibrosis akin to extranodal IgG4-RD or diffuse interfollicular expansion by IgG4-positive plasma cells are highly specific features of true IgG4-related lymphadenopathy. Our findings provide for a clinically meaningful approach to the evaluation of lymph nodes that will assist pathologists in distinguishing IgG4-related lymphadenopathy from its mimics.

9 August 2015 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
DTDmitry S. Trifanov
Dmitry S. Trifanov
MDManish Dhyani
Manish Dhyani
JBJacob R. Bledsoe
Jacob R. Bledsoe
JMJoseph Misdraji
Joseph Misdraji
ABAtul K. Bhan
Atul K. Bhan
ASAnthony E. Samir
Anthony E. Samir